Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China

doi:10.3748/wjg.14.2715

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 17

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4035)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

479

HTML

2985

Figures (1-3)

269

Tables (1-5)

302

Sum=4035

May 7, 2008 (publication date) through Feb 11, 2025

Times Cited of This Article

Times Cited (30)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Gastric Cancer

World J Gastroenterol. May 7, 2008; 14(17): 2715-2722
Published online May 7, 2008. doi: 10.3748/wjg.14.2715

Table 4 Direct medical cost-effectiveness analyses

Regimens	Cost (￥, RMB)	Incr cost (￥, RMB)	Eff	Incr Eff	C/E (￥, RMB)	Incr C/E (ICER) (￥, RMB)
DMC/MST analyses
5Fu+CF+ADM+MTX (FAMTX)¹	1756.95	-	6.1	-	288.02	Baseline
5Fu+ADM/EPI+MMC (FAM)	1978.23	221.28	10.8	4.7	183.17	47.08
UFT+DDP+VP-16 (FEP)	1999.97	21.74	10.0	-0.8	200.00	Dominated
5Fu+EPI+DDP (ECF)	2276.43	298.20	8.7	-2.1	261.66	Dominated
UFT+MMC (UFTM)	2441.29	463.06	8.5	-2.3	287.21	Dominated
5Fu+VP-16+CF (ELF)	2543.12	564.89	11.7	0.9	217.36	627.66
DDP+VP-16+ADM/EPI (EAP)	2790.23	247.11	8.5	-3.2	328.26	Dominated
5FU+CF+DDP+MMC (LFP/M)	3056.08	512.96	9.0	-2.7	339.56	Dominated
DMC/CR+PR analyses
5Fu+CF+ADM+MTX (FAMTX)¹	1756.95	-	21.0	-	83.66	Baseline
5Fu+ADM/EPI+MMC (FAM)	1978.23	221.28	38.1	17.1	51.92	Extended dominance
UFT+DDP+VP-16 (FEP)	1999.97	21.74	47.1	9	42.46	2.42
5Fu+EPI+DDP (ECF)	2276.43	276.46	44.4	-2.7	51.27	Dominated
UFT+MMC (UFTM)	2441.29	441.32	32.7	-14.4	74.66	Dominated
5Fu+VP-16+CF (ELF)	2543.12	543.15	53.3	6.2	47.71	87.6
5FU+DDP+PTX (TCF)	2667.01	123.89	50.0	-3.3	53.34	Dominated
DDP+VP-16+ADM/EPI (EAP)	2790.23	247.11	52.5	-0.8	53.15	Dominated
5FU+CF+DDP+MMC (LFP/M)	3056.08	512.96	44.0	-9.3	69.46	Dominated
5FU+CF+L-OHP (FOLFOX)	3244.31	701.19	50.0	-3.3	64.89	Dominated
5FU+CF+DXL+DDP (DCF)	9979.00	7435.88	56.3	3.0	177.25	2478.63

¹FAMTX regimen was selected as the common baseline for other regimens to refer to. Incr cost: Incremental cost; Eff: Effectiveness; Incr Eff: Incremental effectiveness; CR: Complete response; PR: Partial response; MST: Median survival time; DMC: Per capita direct medical cost of single cycle; 5FU: 5-fluorouracil; ADM: Adriamycin; EPI: Epirubicin; MMC: Mitomycin; DDP: Cisplatin; VP-16: Etoposide; CF: Calcium Leucovorin; UFT: Uracil-tegafur; MTX: Methotrexate; PTX: Paclitaxel; DXL: Docetaxel; L-OHP: Oxaliplatin.

Citation: Chen XZ, Jiang K, Hu JK, Zhang B, Gou HF, Yang K, Chen ZX, Chen JP. Cost-effectiveness analysis of chemotherapy for advanced gastric cancer in China. World J Gastroenterol 2008; 14(17): 2715-2722
URL: https://www.wjgnet.com/1007-9327/full/v14/i17/2715.htm
DOI: https://dx.doi.org/10.3748/wjg.14.2715